Nexentis Technologies Inc(NXTS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 5:16 PM ET (Korea 10/24 06:16)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -87.6 | Insider Own | 48.07% | Shs Outstand | 1.4M | Perf Week | -18.74% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.8M | Perf Month | -64.1% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | - | Inst Own | 4.36% | Short Float | 5.03% | Perf Quarter | -68.61% |
| Income | -0.01B | P/S | 3.61 | EPS this Y | - | Inst Trans | 21.08% | Short Ratio | 0.11 | Perf Half Y | -89.52% |
| Sales | 0.00B | P/B | 0.4 | EPS next 5Y | - | ROA | -79.42% | Short Interest | 0.04M | Perf YTD | -95.54% |
| Book/sh | 1.31 | P/C | 0.08 | EPS past 3/5Y | 79.28% 57.47% | ROE | -93.11% | 52W High | -98.27% ($30.28) | Perf Year | -98.17% |
| Cash/sh | 6.17 | P/FCF | - | Sales past 3/5Y | - | ROIC | -316.15% | 52W Low | 3.88% ($0.50) | Perf 3Y | -99.9% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 77.92% | Gross Margin | 63.56% | Volatility(W/M) | 11.78% 11.91% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | -37.39 | Sales Y/Y TTM | 18.94% | Oper. Margin | -2641.93% | ATR (14) | 0.13 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 3.72 | EPS Q/Q | 24.45% | Profit Margin | -3208.23% | RSI (14) | 18.29 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.72 | Sales Q/Q | -100% | SMA20 | -45.09% ($0.95) | Beta | 1.93 | Target Price | - |
| Payout | - | Debt/Eq | 0.23 | Earnings | - | SMA50 | -62.14% ($1.37) | Rel Volume | 0.09 | Prev Close | $0.57 |
| Employees | 9 | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | - | SMA200 | -88.09% ($4.37) | Avg Volume(3M) | 0.35M | Price | $0.52 |
| IPO | 2010/11/12 | Option/Short | No/Yes | Trades | 160 | Volume | 30,821 | Change | -7.55% |
🧬 This AI- and data-driven mitochondrial biotech company changed its name from the former N2OFF. It operates MitoCareX Bio as a subsidiary, focused on discovering and developing drug candidates for cancer and metabolic/inflammatory diseases by targeting the mitochondrial SLC25 transporter family. At the same time, it also manages non-core assets through investments in European solar projects.
Over the past 1 year, on the lower side
98% below its 1-year high.
Traded less than usual. That is 9% of its average volume.
NXTS has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $361. Peers typically go for $120.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
TEMC Corgi TEM 2x Daily ETF <0.01% It ranks #13 of 13 in the industry
Based on market cap of $1M.
IPI#9 Intrepid Potash Inc $420M PER 31.6 
AVD#10 American Vanguard Corp $30M PER - 
BIOX#11 Bioceres Crop Solutions Corp $15M PER - 
SEED#12 Origin Agritech Ltd $12M PER - NXTS#13 Nexentis Technologies Inc $1M PER - 
FAQ
What kind of company is NXTS?
NXTS belongs to the Basic Materials sector and operates in the Agricultural Inputs industry.
What is the market cap of NXTS?
The market cap of NXTS is approximately $1M, ranking 5,875 within its sector.
What is the 52-week high and low for NXTS?
NXTS has recorded a 52-week high of $30.28 and a low of $0.50.
